| Document |
Document Title |
|
WO/2024/037527A1 |
Provided herein are heteroaromatic compounds which target BTK proteins for ubiquitination and proteasomal degradation. Also provided herein are methods for using said compounds for the treatment of diseases.
|
|
WO/2024/038378A1 |
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and...
|
|
WO/2024/038282A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, Y and B are as ...
|
|
WO/2024/037608A1 |
Provided is a PRMT5 inhibitor represented by formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a solvate thereof. Also provided is a method for prepa...
|
|
WO/2024/037520A1 |
Disclosed in the present invention are a new compound as represented by general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer and a racemate thereof, and a pharmaceutical composition containing the compo...
|
|
WO/2024/040080A1 |
The present embodiments provide compounds of Formula I, compositions of the compounds, and methods for treating diseases such as cancer.
|
|
WO/2024/038860A1 |
An onium salt of a nitrogen-containing (hetero)aryl compound according to the present invention is represented by formula (I) (in the formula, Q1 represents a pyrazole ring or the like, G1 represents a nitrogen or carbon atom, X1 represe...
|
|
WO/2024/038398A1 |
The present invention provides a novel 5-fluoro-1-[(2-fluorophenyl) methyl]-1H-pyrazolo [3, 4-b] pyridine-3-carboximidamide formate compound of formula (IV) and process for preparation thereof. The present invention further provides for ...
|
|
WO/2024/039250A1 |
The present invention relates to a new class of methanogen inhibitors for ruminants. The invention also extends to the use of such compounds in ruminants to reduce methane production in the rumen and/or to enhance productivity in the rum...
|
|
WO/2024/038436A1 |
The present invention relates to the preparation of cyantraniliprole, comprising the preparation of 8-methyl-2,4-dioxo-l,4-dihydro-2H-benzo[d][l,3]oxazine-6-car
bonitrile key intermediate via 2-amino-5-((hydroxyimino)methyl)-3-methylbenz...
|
|
WO/2024/037668A1 |
Disclosed are a 2-nitrogen-substituted pyrimidine compound represented by formula I, a respective optical isomer, a deuterated substance, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising th...
|
|
WO/2024/039829A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
|
|
WO/2024/032774A1 |
Provided are a compound as a voltage-gated sodium channel inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The compound has the structural characteristics of formula (I).
|
|
WO/2024/034593A1 |
Provided is a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer. The present inventors examined compounds useful as an active ingredient of a pharmaceutical compos...
|
|
WO/2024/036218A1 |
Provided is the use of isocitrate dehydrogenase (IDH1 and IDH2) mutations for selecting and treating cancer patients for zotiraciclib (TG02) therapy, for example, in treating cancers such as glioma, medulloblastoma, chondrosarcoma, chola...
|
|
WO/2024/036112A1 |
Described herein are amide prodrugs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating a CNS disease or disorder.
|
|
WO/2024/034657A1 |
The present invention addresses the problem of providing a pharmaceutical composition for cancer treatment of colorectal cancer and/or lung cancer. The present inventors have studied compounds useful as an active ingredient for a pharm...
|
|
WO/2024/036270A1 |
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
|
|
WO/2024/035626A1 |
Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to ...
|
|
WO/2024/034652A1 |
The present disclosure provides: a tertiary amide derivative substituted by quaternary carbon that is useful as a medicine and a pharmaceutically acceptable salt of the tertiary amide derivative; a pharmaceutical composition comprising t...
|
|
WO/2024/035771A2 |
The present disclosure provides compounds of Formula (I), Formula (II) and Formula (III) which are useful as inhibitors of ULK3 and methods of using the same to treat cancers, such as ULK-associated cancers, for example multiple myeloma ...
|
|
WO/2024/032661A1 |
The present invention relates to the technical field of medicine, in particular to a KIF18A inhibitor compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer thereof, a pharmaceutical composition and prep...
|
|
WO/2024/032529A1 |
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...
|
|
WO/2024/033353A1 |
The present invention relates to a compound, an organic semiconducting material comprising the same, an organic electronic device comprising the same and a display device comprising the same.
|
|
WO/2024/035950A1 |
Provided are compounds of the Formula (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
|
|
WO/2024/032600A1 |
Disclosed are a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, and a use thereof in...
|
|
WO/2024/035627A1 |
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
|
|
WO/2024/032689A1 |
The present disclosure relates to a compound of formula (I) or a salt thereof, an enantiomer thereof, a stereoisomer thereof, a solvate thereof, or a polymorph thereof, and use thereof. The present disclosure further relates to a pharmac...
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/032751A1 |
The present disclosure relates to a crystal form of a substituted 2-hydro-pyrazole derivative (I) and a method for preparing same, and further comprises use of the crystal form in preparing drugs for treating breast cancer and other canc...
|
|
WO/2024/032584A1 |
The present invention relates to a protein tyrosine kinase inhibitor for treating protein tyrosine kinase-mediated proliferative diseases or symptoms, such as ocular diseases and malignant tumors accompanied by pathological neoangiogenes...
|
|
WO/2024/035194A1 |
The present invention relates to a novel heteroaryl-substituted derivative and a composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases comprising same. The heteroaryl-substituted derivative ...
|
|
WO/2024/036100A1 |
Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, Z, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (...
|
|
WO/2024/033322A1 |
The present invention relates to a metal complex, a semiconductor layer comprising the metal complex and an organic electronic device comprising at least one metal complex thereof.
|
|
WO/2024/032410A1 |
The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.
|
|
WO/2024/034591A1 |
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating cancer, in particular, pancreatic cancer. The present inventors examined compounds useful as an active ingredient of a pharmaceutical com...
|
|
WO/2024/032782A1 |
Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...
|
|
WO/2024/035925A2 |
Disclosed herein is a PET tracer compound N-cyclopropyl-1-(4-(4-(fluoro-18F)phenyl) pyrimidin-5-yl)-N-methyl piperidine-4-carboxamide or salt thereof, and uses as an imaging agent. In certain embodiments, this disclosure relates to precu...
|
|
WO/2024/027457A1 |
A compound which has EV71 and/or CVA16 virus inhibitory activity and an application thereof, belonging to the field of antiviral drugs. The compound has the structure of formula (I), has good EV71 and/or CVA16 virus replication inhibitor...
|
|
WO/2024/029489A1 |
Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...
|
|
WO/2024/028782A1 |
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relat...
|
|
WO/2024/031089A1 |
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
|
|
WO/2024/027795A1 |
An antibody-drug conjugate containing an Myc protein degradation agent bioactive compound, a preparation method therefor, and use thereof in preventing and/or treating diseases related to abnormal cell activity, including but not limited...
|
|
WO/2024/027703A1 |
Provided are a PRMT5 inhibitor, and a preparation method therefor and a use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a use thereof in ...
|
|
WO/2024/027712A1 |
Disclosed in the present invention are a nitrogen-containing heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a compound as represented by formula (II). The compound has a goo...
|
|
WO/2024/027694A1 |
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...
|
|
WO/2024/028795A1 |
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon l...
|
|
WO/2024/028363A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
|
WO/2024/028364A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
